Sardine-Enriched Diet Could Lessen Likelihood of Developing Diabetes

Consuming a sardine-enriched diet may prevent the development of type 2 diabetes, according to a study recently published in Clinical Nutrition.

Researchers led by Diana A. Diaz-Rizzolo, PhD, of the Open University of Catalonia in Barcelona, Spain, point out that consuming fish could play a role in preventing diabetes, but the specific types of fish that offer that protection haven’t been identified. Sardines are rich in omega-3 and taurine, which the authors write could delay the development of type 2 diabetes. The authors hypothesized that the consuming sardines twice a week for one year could reduce the risk of developing type 2 diabetes in a population with prediabetes and old age.

Consuming sardines twice a week for one year could reduce the risk of developing type 2 diabetes in a population with prediabetes and old age.

The researchers recruited 152 participants with fasting glucose between 100-124 mg/dL and aged ≥65 and randomly distributed these patients into two groups: the sardine group and the control group. “Both groups received same [type 2 diabetes]-prevention nutritional during a year but only [the sardine group] had to add 200 g of sardine per week,” the authors write. “All variables were collected before to start and at the end of the diet.”

Participants in the sardine group showed an increase in HDL-cholesterol and adiponectin and a decrease in triglycerides and blood pressure, as well as a lower HOMA-IR. Based on these results, the authors conclude that a year of consuming a sardine-rich diet has a greater protective effect against developing type 2 diabetes and cardiovascular events.

 

You may also like

  • Circulating microRNAs Likely as Effective as A1C for Predicting Type 2 Diabetes in Youth

    Measuring the circulating abundance of microRNAs is likely as effective as measuring the level of sugar in the blood for determining how a young person with the condition will fare, according to a study recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Jeanie Tryggestad, MD, an associate professor of pediatrics…

  • Two Medication Classes Reduced Cardiovascular and Liver Events in People with Type 2 Diabetes

    GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data presented at ENDO 2024. Researchers reviewed Medicare data documented from 2013 to 2020 and a large U.S. health insurance database from 2013 to 2022. They performed…